USD
+$0.00
(+0.00%
)At Close (As of Sep 26, 2025)
$730.95M
Market Cap
-
P/E Ratio
-1.21
EPS
$12.51
52 Week High
$1.64
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $40M |
Total Revenue | $164M |
Cost Of Revenue | $124M |
Costof Goods And Services Sold | $124M |
Operating Income | -$395M |
Selling General And Administrative | $52M |
Research And Development | $282M |
Operating Expenses | $435M |
Investment Income Net | - |
Net Interest Income | $20M |
Interest Income | $20M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $44M |
Income Before Tax | -$375M |
Income Tax Expense | -$2.8M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$372M |
Comprehensive Income Net Of Tax | - |
Ebit | -$395M |
Ebitda | -$352M |
Net Income | -$372M |
Field | Value (USD) |
---|---|
Total Assets | $910M |
Total Current Assets | $457M |
Cash And Cash Equivalents At Carrying Value | $116M |
Cash And Short Term Investments | $116M |
Inventory | $52M |
Current Net Receivables | $69M |
Total Non Current Assets | $453M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $282M |
Intangible Assets Excluding Goodwill | $282M |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $208M |
Other Current Assets | $12M |
Other Non Current Assets | - |
Total Liabilities | $200M |
Total Current Liabilities | $122M |
Current Accounts Payable | $28M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $26M |
Total Non Current Liabilities | $78M |
Capital Lease Obligations | $57M |
Long Term Debt | $1M |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $58M |
Other Current Liabilities | $69M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $710M |
Treasury Stock | - |
Retained Earnings | -$2.4B |
Common Stock | $13K |
Common Stock Shares Outstanding | $290M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$353M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $44M |
Capital Expenditures | $11M |
Change In Receivables | - |
Change In Inventory | -$40M |
Profit Loss | - |
Cashflow From Investment | -$96M |
Cashflow From Financing | $391M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$372M |
Field | Value (USD) |
---|---|
Gross Profit | $40M |
Total Revenue | $164M |
Cost Of Revenue | $124M |
Costof Goods And Services Sold | $124M |
Operating Income | -$395M |
Selling General And Administrative | $52M |
Research And Development | $282M |
Operating Expenses | $435M |
Investment Income Net | - |
Net Interest Income | $20M |
Interest Income | $20M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $44M |
Income Before Tax | -$375M |
Income Tax Expense | -$2.8M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$372M |
Comprehensive Income Net Of Tax | - |
Ebit | -$395M |
Ebitda | -$352M |
Net Income | -$372M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Iovance Biotherapeutics, Inc. is a pioneering clinical-stage biotechnology company based in San Carlos, California, dedicated to advancing cancer immunotherapy through innovative cell therapy solutions. The company's proprietary tumor-infiltrating lymphocyte (TIL) therapy aims to leverage and enhance the patient’s immune response to combat various cancer types, with a current focus on melanoma and cervical cancer. With a robust pipeline and a commitment to scientific excellence, Iovance is positioned to address significant unmet medical needs in oncology, making it a compelling investment opportunity in the rapidly evolving field of cancer treatment.